ISB News

Dr. Naeha Subramanian Promoted to Associate Professor

Dr. Naeha Subramanian

ISB’s Dr. Naeha Subramanian has been promoted to Associate Professor. “This is a tremendous time to be a scientist, specifically at ISB. We are living through a time when the impact of immunology on society cannot be overstated,” she said. (Steve Utaski/Remedy Pictures)

Dr. Naeha Subramanian – an expert in immunology, innate immunity, and host-pathogen interactions, and head of ISB’s Subramanian Lab – has been promoted to Associate Professor.

“Naeha is an engaged and active member of the ISB community, contributing to our lecture series, educational programs and faculty discussions,” said ISB President Dr. Jim Heath. “She and the members of her lab are to be congratulated for their recent publications and flurry of outstanding scores on federal grants.” 

The Subramanian Lab recently published important research, including news that small, persistent increases in the expression of the immune sensor NOD1 may promote cancer risks, and details of how the bacterium Salmonella conceals itself from the host immune system. The work was published in the journals Science Signaling and Proceedings of the National Academy of Sciences (PNAS), respectively.

“I am honored with this promotion and excited about the incredible research being conducted in my lab. It is a pleasure and privilege to tackle exciting questions everyday,” Subramanian said.

Subramanian was named an Assistant Professor in 2014 when she joined ISB. Prior to that, she worked at the National Institutes of Health for seven years as a research fellow and visiting fellow. She received her PhD from the National Institute of Immunology, and her Bachelor and Master of Science degrees from Delhi University.

“This is a tremendous time to be a scientist, specifically at ISB,” she said. “We are living through a time when the impact of immunology on society cannot be overstated. With passion and purpose, my lab and I hope to further advance our understanding of the immune system in infectious and complex disease in the time ahead.”

Recent Articles

  • ISB President Dr. Jim Heath

    ISB Leading NCI Comprehensive Cancer Center to Study Sequential Targeted Inhibitors and Immunotherapies

    The NCI awarded ISB a 5-year, $13 million grant to lead a comprehensive cancer center and study sequential combinations of targeted inhibitors and immunotherapies. The program is designed to determine if the treatments yield greater patient benefit when administered in sequence rather than as monotherapies or as simultaneously administered combinations.

  • 2022 ISB Virtual Microbiome Series

    2022 ISB Virtual Microbiome Series Announced

    Our multi-day microbiome-themed virtual course and symposium is back for the third year! ISB is hosting a two-day course on October 12 & 13, 2022, followed by a symposium on October 14, 2022 on global perspectives in microbiome research. Both events are virtual and free. The intended audience for these events are graduate students, postdocs, principal investigators, industry scientists, educators, clinicians, or any other variety of microbiome-curious people from across the globe.

  • Bugs vs. Drugs: How Our Microbiomes Can Explain Our Response to Statins

    ISB Assistant Professor Dr. Sean Gibbons talked about the science behind statins in our most recent Research Roundtable virtual presentation. His talk was titled “Bugs vs. Drugs: How Our Unique Gut Microbiomes Shape Our Personalized Responses to Statins.”